Argenx stock after-hours at EUR 815.70: minus 2.59 percent versus prior close
Published on 10/02/2026 at 19:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Argenx traded at EUR 815.70 in after-hours trading at 6:58 p.m. CEST on October 2, 2026, down EUR 21.70, or 2.59 percent, versus the prior Lang & Schwarz close of EUR 837.40.
October 2 trading session
The Lang & Schwarz quote had a bid of EUR 815.00 and an ask of EUR 816.40. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Argenx stock.
New VYVGART data presented
In a September 29, 2026 release, GlobeNewswire reported that argenx SE, listed on Euronext and Nasdaq under ARGX, would present clinical, long-term and real-world data at the AANEM Annual Meeting and the MGFA Scientific Session in Orlando from September 29 through October 2. The presentation program covered VYVGART in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, alongside pipeline candidates empasiprubart and adimanebart.
The release said one-year ADAPT SERON results showed mean MG-ADL improvements of approximately five points maintained through Week 52 in generalized myasthenia gravis patients without detectable anti-AChR antibodies. It also reported that a real-world analysis of more than 1,100 U.S. patients found a mean MG-ADL reduction of 4.7 points over the first three months for patients treated within one year of diagnosis, compared with 3.5 points for those treated more than three years after diagnosis.
